Skip to Content
Merck
CN

Key Documents

View All Documentation

Z-005

Zonisamide solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C8H8N2O3S
CAS Number:
68291-97-4
Molecular Weight:
212.23
NACRES:
NA.24
PubChem Substance ID:
329831593
UNSPSC Code:
41116107
EC Number:
200-659-6
MDL number:
MFCD00865316
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

NS(CC1=NOC2=C1C=CC=C2)(=O)=O

InChI

1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)

InChI key

UBQNRHZMVUUOMG-UHFFFAOYSA-N

Gene Information

human ... SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335)

General description

Zonisamide is a second-generation anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures, infantile spasm, mixed seizure types of Lennox-Gastaut syndrome, and generalized tonic-clonic seizure. Zonisamide is marketed in the US under the trade name Zonegran®.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zonegran is a registered trademark of Dainippon Sumitomo Pharma Co., Ltd.

Disclaimer

Supply conditions do not apply to the regions and states of Brazil: North, Northeast, Mato Grosso do Sul, Mato Grosso, and Rio Grande do Sul.

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes

Storage Class

3 - Flammable liquids

wgk

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Regulatory Information

危险化学品

This item has

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yuto Ueda et al.
Biochemical and biophysical research communications, 428(3), 401-404 (2012-10-30)
The anti-epileptic drug zonisamide is reported to exert beneficial effects in patients with Parkinson's disease. To elucidate the pathophysiological mechanisms underlying the anti-parkinsonism effects of zonisamide, we examined the effect of zonisamide co-administered with levodopa in the striata of rats
M E Choudhury et al.
European journal of pharmacology, 689(1-3), 72-80 (2012-06-05)
Zonisamide has been proven as an effective drug for the recovery of degenerating dopaminergic neurons in the animal models of Parkinson's disease. However, several lines of evidence have questioned the neuroprotective capacity of zonisamide in animal models of Parkinson's disease.
Combination therapy of zonisamide with aripiprazole on ECT- and benzodiazepine-resistant periodic catatonia.
Masanori Nakagawa et al.
The Journal of neuropsychiatry and clinical neurosciences, 24(3), E9-E9 (2012-10-06)
View All Related Papers

Global Trade Item Number

SKUGTIN
Z-005-1ML04061837588266